医学临床研究
  2025年4月6日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2019, Vol. 36 Issue (4): 648-650    DOI: 10.3969/j.issn.1671-7171.2019.04.009
  论著 本期目录 | 过刊浏览 | 高级检索 |
坤泰胶囊联合芬吗通治疗围绝经期综合征患者的疗效观察
付丽侠
成都市妇女儿童中心医院妇女保健中心 ,四川 成都 610091
Observation on the Curative Effect of Kuntai Capsule Combined with Fenmotong(complex packing estradiol) in the Treatment of Perimenopausal Syndrome
FU Li-Xia
The Centre of Women's Health, Chengdu Women and Children Centre Hospital, Chengdu, Sichuan,610091
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨坤泰胶囊联合芬吗通治疗围绝经期综合征患者的疗效观察。【方法】选取2016年10月至2017年10月在本院诊治的围绝经期患者146例,按照随机数表法分为对照组和观察组,每组73例。对照组采用芬吗通治疗,观察组在对照组基础上加用坤泰胶囊,比较两组临床疗效、治疗前后的卵巢功能、生活质量和药物副反应。【结果】两组患者治疗前卵泡刺激素(FSH)、窦卵泡数目(AFC)、黄体生成素(LH)、雌二醇(E2)、更年期生存质量(MENQOL)评分、临床症状评分比较差异均无统计学意义(P>0.05);治疗后,观察组FSH、AFC、LH、E2改善效果明显高于对照组(P<0.05);观察组临床症状评分和MENQOL评分明显低于对照组(P<0.05);观察组总有效率明显高于对照组(P<0.05);两组药物副反应发生率比较差异无统计学意义(P>0.05)。【结论】坤泰胶囊联合芬吗通治疗围绝经期综合征患者,可改善患者临床症状和卵巢功能,提高临床疗效和生活质量,且较为安全,值得临床推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
付丽侠
关键词 围绝经期/生理学综合征药物疗法联合    
Abstract【Objective】To investigate the effect of Kuntai capsule combined with complex packing estradiol(Fenmotong) in the treatment of perimenopausal syndrome.【Methods】A total of 146 perimenopausal patients who were treated in our hospital from October 2016 to October 2017 were randomly divided into control group and observation group. Each group had 73 cases. The control group was given complex packing estradiol cycle sequential treatment. The observation group was given Kuntai Capsule on the basis of the control group. The clinical efficacy, ovarian function, quality of life and adverse drug reactions before and after treatment were compared between the two groups.【Results】There was no significant difference in FSH, AFC, LH, E2, MENQOL and clinical symptom score between the two groups before treatment (P>0.05); after treatment, the improvement effect of FSH, AFC, LH and E2 in the observation group was significantly higher than that in the control group (P<0.05); the clinical symptom score and ENQOL score in the observation group were significantly lower than those in the control group (P<0.05). In the control group (P<0.05), the total effective rate in the observation group was significantly higher than that in the control group (P<0.05); there was no significant difference in the incidence of side effects between the two groups (P>0.05). 【Conclusion】Kuntai capsule combined with Fenmotong in the treatment of perimenopausal syndrome can improve the clinical symptoms and ovarian function of patients, improve the clinical efficacy and quality of life, and is relatively safe, which is worthy of clinical application.
Key wordsPerimenopause/PH    Syndrome    Drug Therapy    Combination
收稿日期: 2018-11-27     
PACS:  R271.116  
引用本文:   
付丽侠. 坤泰胶囊联合芬吗通治疗围绝经期综合征患者的疗效观察[J]. 医学临床研究, 2019, 36(4): 648-650.
FU Li-Xia. Observation on the Curative Effect of Kuntai Capsule Combined with Fenmotong(complex packing estradiol) in the Treatment of Perimenopausal Syndrome. JOURNAL OF CLINICAL RESEARCH, 2019, 36(4): 648-650.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2019.04.009     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2019/V36/I4/648
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn